Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients.
Malard F, Vekhoff A, Lapusan S, Isnard F, D'incan-Corda E, Rey J, Saillard C, Thomas X, Ducastelle-Lepretre S, Paubelle E, Larcher MV, Rocher C, Recher C, Tavitian S, Bertoli S, Michallet AS, Gilis L, Peterlin P, Chevallier P, Nguyen S, Plantamura E, Boucinha L, Gasc C, Michallet M, Dore J, Legrand O, Mohty M. Malard F, et al. Among authors: lapusan s. Nat Commun. 2021 May 25;12(1):3084. doi: 10.1038/s41467-021-23376-6. Nat Commun. 2021. PMID: 34035290 Free PMC article. Clinical Trial.
Interest of cytogenetic and FISH evaluation for prognosis evaluation in 198 patients with acute myeloid leukemia in first complete remission in a single institution.
Hirsch P, Labopin M, Viguié F, Perot C, Isnard F, Mamez AC, Bilhou-Nabera C, Marzac C, Delhommeau F, Lapusan S, Marie JP, Mohty M, Legrand O. Hirsch P, et al. Among authors: lapusan s. Leuk Res. 2014 Aug;38(8):907-12. doi: 10.1016/j.leukres.2014.05.021. Epub 2014 Jun 4. Leuk Res. 2014. PMID: 24957411
Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia.
Debureaux PE, Labopin M, Mamez AC, Lapusan S, Isnard F, Adaeva R, Bonnin A, Hirsch P, Delhommeau F, Battipaglia G, Duléry R, Malard F, Vekhoff A, Mohty M, Legrand O, Brissot E. Debureaux PE, et al. Among authors: lapusan s. Bone Marrow Transplant. 2020 Feb;55(2):452-460. doi: 10.1038/s41409-019-0690-2. Epub 2019 Sep 25. Bone Marrow Transplant. 2020. PMID: 31554931 Free article.
Gemtuzumab Ozogamicin Combined With Intensive Chemotherapy in Patients With Acute Myeloid Leukemia Relapsing After Allogenic Stem Cell Transplantation.
Genthon A, Brissot E, Malard F, van de Wyngaert Z, Bonnin A, Banet A, Marjanovic Z, Ikhlef S, Lapusan S, Sestili S, Corre E, Paviglianiti A, Adaeva R, 'Hammedi-Bouzina FM, Labopin M, Dulery R, Mohty M, Legrand O. Genthon A, et al. Among authors: lapusan s. Clin Lymphoma Myeloma Leuk. 2020 Dec;20(12):791-796. doi: 10.1016/j.clml.2020.07.001. Epub 2020 Jul 6. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32741743
Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia.
Hirsch P, Tang R, Abermil N, Flandrin P, Moatti H, Favale F, Suner L, Lorre F, Marzac C, Fava F, Mamez AC, Lapusan S, Isnard F, Mohty M, Legrand O, Douay L, Bilhou-Nabera C, Delhommeau F. Hirsch P, et al. Among authors: lapusan s. Haematologica. 2017 Jul;102(7):1227-1237. doi: 10.3324/haematol.2016.159681. Epub 2017 Mar 16. Haematologica. 2017. PMID: 28302711 Free PMC article.
Prognostic impact of early minimal residual disease combined with complete molecular evaluation in acute myeloid leukemia with mutated NPM1: a single center study.
Memoli M, Genthon A, Favale F, Lapusan S, Johnson N, Adaeva R, Deswarte C, Battipaglia G, Malard F, Duléry R, Brissot E, Banet A, Van de Wyngaert Z, Mohty M, Delhommeau F, Legrand O, Hirsch P. Memoli M, et al. Among authors: lapusan s. Leuk Lymphoma. 2022 Sep;63(9):2171-2179. doi: 10.1080/10428194.2022.2064987. Epub 2022 Apr 22. Leuk Lymphoma. 2022. PMID: 35459427
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia.
Lapusan S, Vidriales MB, Thomas X, de Botton S, Vekhoff A, Tang R, Dumontet C, Morariu-Zamfir R, Lambert JM, Ozoux ML, Poncelet P, San Miguel JF, Legrand O, DeAngelo DJ, Giles FJ, Marie JP. Lapusan S, et al. Invest New Drugs. 2012 Jun;30(3):1121-31. doi: 10.1007/s10637-011-9670-0. Epub 2011 Apr 26. Invest New Drugs. 2012. PMID: 21519855 Clinical Trial.
Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.
Battipaglia G, Ruggeri A, Massoud R, El Cheikh J, Jestin M, Antar A, Ahmed SO, Rasheed W, Shaheen M, Belhocine R, Brissot E, Dulery R, Eder S, Giannotti F, Isnard F, Lapusan S, Rubio MT, Vekhoff A, Aljurf M, Legrand O, Mohty M, Bazarbachi A. Battipaglia G, et al. Among authors: lapusan s. Cancer. 2017 Aug 1;123(15):2867-2874. doi: 10.1002/cncr.30680. Epub 2017 Apr 7. Cancer. 2017. PMID: 28387928 Free article.
53 results